IRCT20200105046010N101尚未招募Unknown
In-vivo Bioequivalence Study of Linagliptin/Metformin 2.5/1000 mg FC. Tablets of The Test Drug (Kharazmi Pharma, Iran) in Compared with The Reference Drug (Jentadueto® 2.5/1000 mg, Boehringer Ingelheim, Germany) in fasting condition in healthy volunteers
Kharazmi Pharmacy0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28) kg/m^2
- •Informed consent
- •Age (18-55 years old)
排除标准
- •Nicotine consumption history
- •Cardiovascular disease History
- •Liver and kidney disease History
- •Alcohol and opioid addiction
- •Allergy reactions history to Linagliptin or Metformin
研究者
相似试验
尚未招募
不适用
inagliptin / Metformin tablet 2.5/1000mg ABIDI (Liroprim 2.5/1000mg) , In- Vivo Bioequivalence in Iranian healthy volunteers.In this study the bioquivalence of test and brand of LIROPRIM will evaluated..IRCT20200105046010N5Tabriz University of Medical Sciences24
招募中
Unknown
Bioequivalence study of Linagliptin/metformin 2.5/1000 mg tabletThis study is performed on healthy volunteers and drug concentration in whole blood is determined..IRCT20200623047902N38Actover Co.24
尚未招募
不适用
Bioequivalence study of Empagliflozin/ Linagliptin10/5 mgIRCT20200105046010N100Faran Pharmed company24
尚未招募
不适用
igagliptin tablets 5mg ABIDI Pharmaceuticals (TRAJENTA® 5mg Tab) , In- Vivo Bioequivalence in Iranian healthy volunteers.IRCT20200105046010N8Tabriz University of Medical Sciences24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Empagliflozin 10 mg Combined Linagliptin 5 mg Tablet formulations.IRCT20180620040164N69Cosar Pharmaceutical Co.24